American Society of Hematology

SHERPA: Blue

People

  1. Shah
    Shah
  2. Lesokhin
    Lesokhin
  3. Mailankody
    Mailankody
  4. Hultcrantz
    Hultcrantz
  5. Korde
    Korde
  6. Hassoun
    Hassoun
  7. Giralt
    Giralt
  8. Landau
    Landau
  9. Shah
    Shah
  10. Tan
    Tan

Groups

  1. CTCR Scholars (84)
  2. Department of Medicine (84)
  3. Hematologic Malignancies, Division of (84)
  4. Center for Hematologic Malignancies (68)
  5. Hematologic Malignancies Research (67)
  6. Myeloma (67)
  7. Survivorship Research (62)
  8. Sloan Kettering Institute Postdocs (61)
  9. Bone Marrow Transplant (57)
  10. Hematology-Oncology Fellows (57)
Search Within
  1. "Urvi Shah"
Formats
  1. Meeting Abstract (74)
  2. Journal Article (9)
  3. Research Letter (1)
Groups
  1. CTCR Scholars (84)
  2. Department of Medicine (84)
  3. Hematologic Malignancies, Division of (84)
  4. Center for Hematologic Malignancies (68)
  5. Hematologic Malignancies Research (67)
  6. Myeloma (67)

More Groups

People
  1. Urvi Shah (84)
  2. Alexander Lesokhin (65)
  3. Sham Mailankody (61)
  4. Malin Hultcrantz (60)
  5. Neha Korde (58)
  6. Hani Hassoun (57)

More People

Years
  1. 2025 (3)
  2. 2024 (25)
  3. 2023 (16)
  4. 2022 (15)
  5. 2021 (6)
  6. 2020 (8)

More Years

Publications
  1. Blood (76)
  2. Blood Advances (8)

Results (84)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma
    Journal Article

    Adegbite, B.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Restarting teclistamab and talquetamab after prolonged dose delay may not require re–step-up dosing
    Research Letter

    Tan, C. R.; Wang, A.; Nemirovsky, D.; Derkach, A.; Shekarkhand, T.; Hamadeh, I.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes
    Journal Article

    Valtis, Y. K.; Devlin, S.; Shouval, R.; Rejeski, K.; Corona, M.; De Abia, A. L.; Rivas-Delgado, A.; Luttwak, E.; Cassanello, G.; Landego, I.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Belantamab mafodotin, nirogacestat and pomalidomide for patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Hassoun, H.; Tan, C. R.; Korde, N.; Lesokhin, A. M.; Hashmi, H.; Maclachlan, K. H.; Rajeeve, S.; Shah, U. A.; Patel, D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Rajeeve, S.; Costa, B. A.; Jurgens, E. M.; Nishimura, N.; Farzana, T.; Firestone, R. S.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Racial differences in proportion of myeloma cases attributable to modifiable risk factors in the United States, 2016-21
    Meeting Abstract

    Anuraj, A.; Rath, D.; Derkach, A.; Usmani, S. Z.; Shah, U. A.
    Blood (2024)

    Fulltext@MSK | Save
  • Initial results of a phase 1 first-in-human study of cemsidomide (CFT7455), a novel MonoDACTM degrader, with dexamethasone in patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Dhakal, B.; Yee, A. J.; Richardson, P. G.; Ailawadhi, S.; Chhabra, S.; Muchtar, E.; Berdeja, J. G.; Richard, S.; Matous, J.; Shah, U. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma- Interim efficacy results of a randomized clinical trial
    Meeting Abstract

    Rajeeve, S.; Derkach, A.; Devlin, S. M.; Santos, J.; Przemielewska, A.; Sood, T.; Maclachlan, K. H.; Hashmi, H.; Tan, C. R.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Long-term benefits in patient-reported outcomes and time to next anti-myeloma therapy of ciltacabtagene autoleucel (cilta-cel) versus standard of care for patients with lenalidomide-refractory multiple myeloma: Results from the phase 3 CARTITUDE-4 clinical trial
    Meeting Abstract

    Bar, N.; Mina, R.; Mylin, A. K.; Yokoyama, H.; Magen, H.; Alsdorf, W.; Minnema, M. C.; Shune, L. O.; Isufi, I.; Harrison, S. J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Brown, S.; Devlin, S. M.; Costa, B. A.; Farzana, T.; Jurgens, E. M.; Firestone, R. S.; Nath, K.; Chung, D. J.; more...
    Blood (2024)

    Fulltext@MSK | Save